• Clinical science
  • Physician

Management of tachycardia


Tachycardia is defined as a heart rate that exceeds 100/minute. Signs of unstable tachycardia include chest pain, shock, and impaired consciousness. Unstable tachycardia is considered an emergency and should be managed with immediate electrical cardioversion. In stable tachycardias, both the cardiac rhythm (i.e., regular or irregular) and the QRS complex (i.e., narrow-complex tachycardia and wide-complex tachycardias) should be evaluated. Undifferentiated regular supraventricular tachycardia (SVTs) should be initially managed with a trial of vagal maneuvers and, if necessary, IV adenosine. Irregular SVTs are usually caused by atrial fibrillation (Afib) or atrial flutter, which are managed either with a rate control strategy (e.g., with β-blockers or calcium channel blockers) or a rhythm control strategy (i.e., with antiarrhythmics or electrical cardioversion) in combination with risk-based anticoagulation therapy. Undifferentiated wide-complex tachycardias (WCTs) should be managed with electrical cardioversion or pharmacological cardioversion. If a stable patient becomes unstable at any point during management, immediate electrical cardioversion is recommended regardless of the rhythm. The content in this article is organized to first provide management steps for undifferentiated arrhythmias but also includes management for specific rhythms, once identified. Unstable tachycardia without a pulse, ventricular fibrillation, and cardiac arrest are not addressed here (see ACLS).


1. ABCDE survey [1]

  • No pulse: Start CPR (see ACLS).
  • Pulse present: Continue stepwise approach through ABCDE and proceed to the next step.
    • Continuous telemetry
    • Continuous pulse oximetry
    • Crash cart at the bedside
    • Frequent blood pressure assessment
    • Supplemental oxygen as needed
    • Obtain IV access.
    • Identify and treat reversible causes

2. Determine if the patient is stable or unstable

Examine patients for unstable signs of tachycardia so that immediate electrical cardioversion can be initiated if indicated.

3. Obtain a 12-lead ECG

  1. Evaluate whether it is a wide-complex tachycardia (WCT) or narrow-complex tachycardia (NCT).
  2. Determine whether the rhythm is regular or irregular (e.g., RR intervals regular or irregular).
  3. Review previous ECGs if available to look for pre-existing abnormalities that may affect treatment choices, e.g.:

4. Identify and treat the cardiac rhythm according to acute management algorithm

Differential diagnosis of tachycardia based on ECG findings
Rhythm Narrow-complex QRS Wide-complex QRS

Unstable tachycardia with pulse

For unstable tachycardia without a pulse, start CPR (see ACLS).

Signs of unstable tachycardia [1]

Initial management

  • Obtain a crash cart, defibrillator device, suction, bag-mask device, and airway and intubation equipment.
  • Call for help (e.g., urgent cardiology consult and/or anesthesia consult)
  • Administer supplemental oxygen, if needed.
  • If unstable signs of tachycardia are present and instability is likely due to tachycardia, perform immediate electrical cardioversion.
    • HR > 150/min: Unstable signs are likely due to tachycardia.
    • HR 100–150/min: Suspect another underlying condition.

Electrical cardioversion [1][4]

  • Synchronized electrical cardioversion is indicated in almost all unstable patients with tachycardia and a pulse. [1]
  • Defibrillation is only indicated if either of the following is the case: [5]
    • An irregular wide-complex cardiac rhythm is identified.
    • The device fails to synchronize with the patient's cardiac rhythm.

Ensure oxygen is turned off or that the flow of oxygen is moved away from the patient during cardioversion, as oxygen is a flammable gas!

Procedural sedation

Do not delay cardioversion for the sake of sedation!

Synchronized electrical cardioversion [4][1][5]


  • Unstable narrow-complex tachycardia with pulse
  • Unstable regular wide-complex tachycardia with pulse


  • Preparation and procedural sedation
  • Place paddles or electrode pads firmly on the thorax of the patient (anteroapical or anteroposterior position).
  • Choose the synchronized (SYNC) mode of shock on the defibrillator device.
  • Select the recommended dose of electrical energy according to the patient's cardiac rhythm. [5][1][4]
    • Regular narrow-complex tachycardia: 50–100 J biphasic waveform
    • Irregular narrow-complex tachycardia: 120–200 J biphasic waveform (preferred) OR 200 J monophasic [8]
    • Regular wide-complex tachycardia: 100 J biphasic waveform
  • “Clear” the patient.
  • Deliver shock.
  • Reassess the rhythm and check the pulse.

Defibrillation [9]


  • Unstable irregular wide-complex tachycardia with pulse
  • Pulseless patient/cardiac arrest (see ACLS)


  • Preparation and procedural sedation for cardioversion
  • Place paddles or electrode pads firmly on the thorax of the patient (anteroapical or anteroposterior position).
  • Choose the unsynchronized mode of shock on the defibrillator device.
  • Select the defibrillator dose: 120–200 J biphasic waveform. [1]
  • “Clear” the patient.
  • Deliver shock.
  • Reassess the rhythm and check the pulse.

Subsequent management

  • Reversion to sinus rhythm (i.e., successful cardioversion)
    • Urgent cardiology consult
    • Consider anticoagulation.
    • Transfer to ICU or CCU.
    • Continuous telemetry and pulse oximetry
  • Persistent arrhythmia (i.e., failure to cardiovert)
    • Administer a second dose of cardioversion
    • Call for expert help.
    • Consider antiarrhythmic infusion in consultation with a cardiologist.
    • Continue resuscitation.
  • Deterioration to a life-threatening rhythm or pulseless patient: Start CPR (see ACLS).

Stable, regular narrow-complex tachycardia

Approach to management [10]

  1. Determine the underlying rhythm.
  2. Consult cardiology for definitive management and follow-up.

Management of undifferentiated SVT [11][10]

  1. Perform vagal maneuvers. [11]
  2. Reassess the rhythm.
    • Rhythm reverts to normal sinus rhythm: Monitor for recurrence.
    • Regular SVT is identified:
      • No contraindications to adenosine: Administer adenosine.
      • Contraindications to adenosine present: Administer an AV-nodal blocking agent (see below).
    • Irregular SVT is identified: See management of stable, irregular narrow-complex tachycardia.
  3. If regular or undifferentiated SVT persists despite adenosine, administer one of the following:
  4. If regular or undifferentiated SVT persists despite the above measures:
  5. Consult cardiology for definitive management.

If the patient becomes hemodynamically unstable, perform synchronized electrical cardioversion.

Calcium channel blockers should be avoided if there is any concern for ventricular tachycardia, as they can precipitate ventricular fibrillation.

Differential diagnosis of SVT

Rhythm Typical ECG findings [12][10][13] Acute management
Sinus tachycardia [14][10][15]
  • Regular sinus P wave
  • Ventricular rhythm: regular
  • Atrial rate = ventricular rate
  • HR rarely exceeds 150–180/min [13]
  • Identify and treat the underlying cause.
  • Physiological sinus tachycardia: No specific treatment required.
  • Inappropriate sinus tachycardia (IST): cardiology consult to rule out other conditions that closely mimic IST and treat accordingly
Atrioventricular nodal re-entrant tachycardia (AVNRT)
  • P wave rarely detectable
  • Infrequent finding: abnormal P wave before or after a QRS complex
  • Ventricular rhythm (RR interval): regular
  • Pseudo-R wave in V1 and/or a pseudo-S wave in inferior lead
  • HR: 110–250/min

Orthodromic AVRT

  • P wave rarely detectable
  • Ventricular rhythm (RR interval): regular
  • RP interval shorter than PR interval (RP < 70 ms)
  • HR: 120–240/min

Focal atrial tachycardia

  • P wave may be detectable but may be obscured by the T wave of the previous QRS complex.
  • P wave morphology can be abnormal.
  • Ventricular rhythm (RR interval): regular
  • RP interval longer than PR interval (RP > 70 ms)
  • Atrial rate > ventricular rate
  • HR: usually between 100–250/min
Atrial flutter with fixed AV conduction
  • Flutter waves (sawtooth appearance)
  • Ventricular rhythm (RR interval): regular
  • Atrial rate > ventricular rate
  • HR: 75–150/min (depending on conduction)

If it is not possible to differentiate between the different types of SVT and expert consultation is not available, treat tachycardia as undifferentiated SVT.

Stable, irregular narrow-complex tachycardia

Approach to management [1]

  1. Determine the underlying rhythm.
  2. Consult cardiology for definitive management and follow-up.

Differential diagnosis of irregular, narrow-complex tachycardia


Typical ECG findings Acute management
Atrial fibrillation with rapid ventricular response
(Afib with RVR)
  • Fibrillatory waves
  • Rhythm: irregularly irregular
  • PR intervals: not distinguishable
  • Absent isoelectric baseline
  • Atrial rate > ventricular rate
  • HR is variable; in Afib with RVR: 100–180/min
Atrial flutter with variable conduction [10][16][17]
  • Flutter waves (sawtooth appearance)
  • Rhythm: irregularly irregular
  • PR intervals: not distinguishable
  • Atrial rate > ventricular rate
  • HR is variable; typically 100–180/min
Multifocal atrial tachycardia (MAT)[18][10]
  • P waves: ≥ 3 distinct P-wave morphologies
  • Rhythm: irregularly irregular
  • PR interval: distinguishable and variable
  • Isoelectric baseline present and distinct [16]
  • Atrial rate > ventricular rate
  • HR > 100

Afib is the most common cause of irregular NCT, followed by atrial tachycardia. MAT is an uncommon cause of tachyarrhythmia; it is often associated with congestive heart failure and COPD. [10][19]

Management of atrial fibrillation with RVR (and atrial flutter) [16][1]

Rate control [16][1]

Avoid CCBs and β-blockers in decompensated heart failure.

Avoid CCBs, digoxin, and adenosine in patients with pre-excitation because of the risk of the arrhythmia converting to ventricular fibrillation.

Rhythm control (e.g., cardioversion) [16][1][23]

Electrical cardioversion

Pharmacological cardioversion for atrial fibrillation [16]

Further management

  • Consider cardiology consultation for long-term therapy, anticoagulation therapy, and consideration of ablation therapy or surgery.
  • Identify and treat the underlying cause.

Management of multifocal atrial tachycardia [10]

Rhythm control is usually ineffective for MAT. [10]

Stable, wide-complex tachycardia

Establishing the underlying rhythm in a patient with wide-complex tachycardia can be extremely challenging and requires a multifaceted approach. The most critical aspect is to distinguish between ventricular tachycardia (VT) and SVT with accessory pathway, but if this cannot be done in a timely manner any wide-complex tachycardia should be treated as VT, as wide-complex tachycardias are most commonly caused by ventricular arrhythmias. Ventricular fibrillation is an unstable rhythm and is not addressed here. [27][10]


  1. Attach defibrillator pads to the patient.
  2. Ensure that the rhythm is stable.
  3. Check 12-lead ECG and perform a brief, focused history (if there is time).
  4. Determine whether the rhythm is more likely to be ventricular or supraventricular in origin (e.g., Brugada criteria) [1]
  5. Urgent cardiology consultation for definitive rhythm identification, management, and follow-up (see differential diagnoses of wide-complex tachycardia)
  6. Identify and treat the underlying cause (e.g., cardiac glycoside poisoning, myocardial ischemia).

If it is not possible to quickly identify the underlying rhythm as SVT or VT, it is safest to treat empirically as VT with synchronized electrical cardioversion (100 J) or with IV procainamide.

Adenosine and AV nodal blocking agents are contraindicated in unstable, irregular, and polymorphic (e.g., Torsades des pointes) wide-complex tachycardias. In SVT with accessory pathway (e.g., Afib with WPW), the AV blockade caused by adenosine can lead to V-Fib due to unrestricted conduction of rapid atrial impulses through the accessory pathway.

Differentiating between VT and SVT

  • There are multiple tools and strategies available, all with advantages and disadvantages.
  • The Brugada criteria is a commonly used algorithm to differentiate between VT and SVT in regular wide-complex tachycardia. [29]
Brugada criteria [30]
ECG finding VT SVT
Absence of RS in all precordial leads? Yes No
R:S interval > 100 ms in one precordial lead? Yes No
AV dissociation present? Yes No
Morphology consistent with VT in leads V1-2 and V6? Yes No


  • If the answer to any is yes: most likely VT
  • If none are present: most likely SVT

Management of stable, undifferentiated ventricular tachycardia [1][31][32]

Pharmacological cardioversion (IV antiarrhythmics)

Do not administer a second antiarrhythmic without expert consultation. [1]

Adenosine is contraindicated in polymorphic WCT and irregular WCT because of the risk of triggering ventricular fibrillation. Verapamil is contraindicated in WCT because of the risk of profound hypotension and cardiac arrest.

Electrical cardioversion

If it is unclear if a ventricular tachycardia is monomorphic or polymorphic, use defibrillation.

Further management

Differential diagnosis of wide-complex tachycardia

Rhythm Typical ECG findings Acute management
Monomorphic ventricular tachycardia [36][4][1][31]
Polymorphic ventricular tachycardia Undifferentiated polymorphic ventricular tachycardia [36][1][31][37]
  • Rate: 120–300/min
  • Wide QRS complexes with variable morphology
  • Rhythm: usually irregular

Torsades de pointes [1][37][38][31][36]

Brugada syndrome [1][31]
Supraventricular tachycardia (SVT)

SVT with an accessory pathway [12][10][1][41][28]

  • Rate: typically > 200/minute
  • Rhythm: usually irregular
  • Absence of bundle branch block
  • Resting ECG: may show pre-excitation pattern [1]

SVT without an accessory pathway


  • Rhythm: usually regular
  • Rate: rarely > 200/minute, typically 120–150/minute
  • Bundle branch block usually present.
    • RBBB (with left hemiblock or right hemiblock)
    • LBBB
  • See management of stable, narrow-complex tachycardia
  • Administer adenosine with caution and under continuous cardiac monitoring.
Ventricular pacing (e.g., pacemaker-induced) [44][45][46][47]
  • Pacing spikes are typically present but may be buried.
  • Sensor-driven tachycardia : rate usually ≤ 160–180/minute
  • Pacemaker-mediated tachycardia : rate usually ≤ 160–180/minute
  • Runaway pacemaker : rate usually ≥ 150–200/minute
  • Place a magnet over the pacemaker.
  • Cardiology consult for pacemaker interrogation and troubleshooting
  • Urgent replacement for runaway pacemaker
  • 1. Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18_suppl_3): pp. S729–S767. doi: 10.1161/circulationaha.110.970988.
  • 2. Keating L. Electrocardiographic features of Wolff-Parkinson-White syndrome. Emerg Med J. 2003; 20(5): pp. 491–493. doi: 10.1136/emj.20.5.491.
  • 3. Ali R, Tahir A, Nadeem M, Shakhatreh MI, Faulknier B. Antidromic Atrioventricular Reentry Tachycardia with Wolff Parkinson White Syndrome: A Rare Beast. Cureus. 2018. doi: 10.7759/cureus.2642.
  • 4. American Heart Association. Advanced Cardiovascular Life Support: Provider Manual. American Heart Association; 2016.
  • 5. Link MS, Atkins DL, Passman RS, et al. Part 6: Electrical Therapies: Automated External Defibrillators, Defibrillation, Cardioversion, and Pacing * 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18_suppl_3): pp. S706–S719. doi: 10.1161/circulationaha.110.970954.
  • 6. Lewis SR, Nicholson A, Reed SS, Kenth JJ, Alderson P, Smith AF. Anaesthetic and sedative agents used for electrical cardioversion. Cochrane Database of Systematic Reviews. 2015. doi: 10.1002/14651858.cd010824.pub2.
  • 7. Brown TB, Lovato LM, Parker D. Procedural sedation in the acute care setting. Am Fam Physician. 2005; 71(1): pp. 85–90. pmid: 15663030.
  • 8. Page RL, Kerber RE, Russell JK, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002; 39(12): pp. 1956–63. doi: 10.1016/s0735-1097(02)01898-3.
  • 9. Panchal AR, Berg KM, Kudenchuk PJ, et al. 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018; 138(23). doi: 10.1161/cir.0000000000000613.
  • 10. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation. 2016; 133(14): pp. e506–e574. doi: 10.1161/cir.0000000000000311.
  • 11. Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015; 386(10005): pp. 1747–1753. doi: 10.1016/s0140-6736(15)61485-4.
  • 12. Walls R, Hockberger R, Gausche-Hill M. Rosen's Emergency Medicine. Philadelphia, PA: Elsevier Health Sciences; 2018.
  • 13. Goldberger AL. Clinical Electrocardiography. Mosby; 2006.
  • 14. Meek S. ABC of clinical electrocardiography: Introduction. II---Basic terminology. BMJ. 2002; 324(7335): pp. 470–473. doi: 10.1136/bmj.324.7335.470.
  • 15. Olshansky B, Sullivan RM. Inappropriate Sinus Tachycardia. J Am Coll Cardiol. 2013; 61(8): pp. 793–801. doi: 10.1016/j.jacc.2012.07.074.
  • 16. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2014; 64(21): pp. e1–e76. doi: 10.1016/j.jacc.2014.03.022.
  • 17. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019; 74(1): pp. 104–132. doi: 10.1016/j.jacc.2019.01.011.
  • 18. Blomström-lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias: Executive Summary. Circulation. 2003; 108(15): pp. 1871–1909. doi: 10.1161/01.CIR.0000091380.04100.84.
  • 19. Colucci RA, Silver MJ, Shubrook J. Common types of supraventricular tachycardia: diagnosis and management. Am Fam Physician. 2010; 82(8): pp. 942–52. pmid: 20949888.
  • 20. Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. N Engl J Med. 2019; 380(16): pp. 1499–1508. doi: 10.1056/nejmoa1900353.
  • 21. Atzema CL, Barrett TW. Managing atrial fibrillation. Ann Emerg Med. 2015; 65(5): pp. 532–9. doi: 10.1016/j.annemergmed.2014.12.010.
  • 22. DeSimone CV, Naksuk N, Asirvatham SJ. Supraventricular Arrhythmias: Clinical Framework and Common Scenarios for the Internist. Mayo Clinic Proceedings. 2018; 93(12): pp. 1825–1841. doi: 10.1016/j.mayocp.2018.07.019.
  • 23. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019; 140(2). doi: 10.1161/cir.0000000000000665.
  • 24. Stiell IG, Birnie D. Managing Recent-Onset Atrial Fibrillation in the Emergency Department. Ann Emerg Med. 2011; 57(1): pp. 31–32. doi: 10.1016/j.annemergmed.2010.04.006.
  • 25. Stiell IG, Clement CM, Perry JJ, et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010; 12(03): pp. 181–191. doi: 10.1017/s1481803500012227.
  • 26. Stiell IG, Clement CM, Rowe BH, et al. Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. Ann Emerg Med. 2017; 69(5): pp. 562–571.e2. doi: 10.1016/j.annemergmed.2016.10.013.
  • 27. B Garner J, M Miller J. Wide Complex Tachycardia - Ventricular Tachycardia or Not Ventricular Tachycardia, That Remains the Question. Arrhythmia & electrophysiology review. 2013; 2(1): pp. 23–9. doi: 10.15420/aer.2013.2.1.23.
  • 28. Nelson JA, Knowlton KU, Harrigan R, Pollack ML, Chan TC. Electrocardiographic manifestations: wide complex tachycardia due to accessory pathway. J Emerg Med. 2003; 24(3): pp. 295–301. doi: 10.1016/s0736-4679(02)00764-3.
  • 29. Isenhour JL, Craig S, Gibbs M, Littmann L, Rose G, Risch R. Wide-complex Tachycardia: Continued Evaluation of Diagnostic Criteria. Academic Emergency Medicine. 2000; 7(7): pp. 769–773. doi: 10.1111/j.1553-2712.2000.tb02267.x.
  • 30. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991; 83(5): pp. 1649–1659. doi: 10.1161/01.cir.83.5.1649.
  • 31. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation. 2018; 138(13): pp. e210–e271. doi: 10.1161/cir.0000000000000548.
  • 32. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol. 2018; 72(14): pp. e91–e220. doi: 10.1016/j.jacc.2017.10.054.
  • 33. Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017; 38(17): pp. 1329–1335. doi: 10.1093/eurheartj/ehw230.
  • 34. Vera A, Cecconi A, Nogales-Romo MT, et al. Wide QRS Complex Tachycardia. Circulation. 2018; 137(13): pp. 1407–1409. doi: 10.1161/circulationaha.118.033936.
  • 35. Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. Texas Heart Institute journal. 2011; 38(2): pp. 111–21. pmid: 21494516.
  • 36. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support. Circulation. 2015; 132(18 suppl 2): pp. S444–S464. doi: 10.1161/cir.0000000000000261.
  • 37. Choudhuri I, Pinninti M, Marwali MR, Sra J, Akhtar M. Polymorphic Ventricular Tachycardia—Part I: Structural Heart Disease and Acquired Causes. Curr Probl Cardiol. 2013; 38(11): pp. 463–496. doi: 10.1016/j.cpcardiol.2013.07.001.
  • 38. ESC Committee for Practice Guidelines, ACC/AHA (Practice Guidelines) Task Force Members. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Eur Heart J. 2006; 27(17): pp. 2099–2140. doi: 10.1093/eurheartj/ehl199.
  • 39. Dakkak M, Baxi K, Patel A. Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome. Case Reports in Cardiology. 2015; 2015: pp. 1–5. doi: 10.1155/2015/753537.
  • 40. Brodie OT, Michowitz Y, Belhassen B, et al. Pharmacological Therapy in Brugada Syndrome. Arrhythmia & Electrophysiology Review. 2018; 7(2): p. 135. doi: 10.15420/aer.2018.21.2.
  • 41. Fengler BT, Brady WJ, Plautz CU. Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED. Am J Emerg Med. 2007; 25(5): pp. 576–583. doi: 10.1016/j.ajem.2006.10.017.
  • 42. Dietel M, Suttorp N, Zeitz M, et al. Harrisons Innere Medizin (2 Bände). ABW Wissenschaftsverlagsgesellschaft (2005); 2005.
  • 43. Edhouse J. ABC of clinical electrocardiography: Broad complex tachycardia---Part I. BMJ. 2002; 324(7339): pp. 719–722. doi: 10.1136/bmj.324.7339.719.
  • 44. Safavi-Naeini P, Saeed M. Pacemaker Troubleshooting: Common Clinical Scenarios. Texas Heart Institute Journal. 2016; 43(5): pp. 415–418. doi: 10.14503/thij-16-5918.
  • 45. Alasti M, Machado C, Rangasamy K, et al. Pacemaker‐mediated arrhythmias. Journal of Arrhythmia. 2018; 34(5): pp. 485–492. doi: 10.1002/joa3.12098.
  • 46. Ortega D, Sammartino M, Pellegrino G, et al. Runaway pacemaker: A forgotten phenomenon?. EP Europace. 2005; 7(6): pp. 592–597. doi: 10.1016/j.eupc.2005.06.004.
  • 47. Gul A, Sheikh MA, Rao A. Runaway pacemaker. BMJ Case Reports. 2019; 12(3): p. e225411. doi: 10.1136/bcr-2018-225411.
  • Kweon KH, Park BH, Cho CG. The Effects of L-thyroxine Treatment on QT Dispersion in Primary Hypothyroidism. J Korean Med Sci. 2007; 22(1): p. 114. doi: 10.3346/jkms.2007.22.1.114.
  • Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsade de Pointes in Hospital Settings. Circulation. 2010; 121(8): pp. 1047–1060. doi: 10.1161/circulationaha.109.192704.
  • Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm. 2017; 14(1): pp. e41–e44. doi: 10.1016/j.hrthm.2016.09.012.
  • Ben Yedder N, Roux JF, Paredes FA. Troponin Elevation in Supraventricular Tachycardia: Primary Dependence on Heart Rate. Can J Cardiol. 2011; 27(1): pp. 105–109. doi: 10.1016/j.cjca.2010.12.004.
  • Mitchell LB. Empiric Antiarrhythmic Drug Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Coll Cardiol. 2009; 54(7): pp. 616–617. doi: 10.1016/j.jacc.2009.05.020.
  • Corrado D, Wichter T, Link MS, et al. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation. 2015; 132(5): pp. 441–453. doi: 10.1161/circulationaha.115.017944.
  • Chockalingam P, Crotti L, Girardengo G, et al. Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2. J Am Coll Cardiol. 2012; 60(20): pp. 2092–2099. doi: 10.1016/j.jacc.2012.07.046.
  • Klein I, Danzi S. Thyroid Disease and the Heart. Circulation. 2007; 116(15): pp. 1725–1735. doi: 10.1161/circulationaha.106.678326.
last updated 05/21/2020
{{uncollapseSections(['zf1rKT0', '-f1DKT0', 'ZT1Z6T0', '4g13vT0', 'aT1Q6T0', 'oh10Ug0'])}}